BCM
CSCI

Bridgeway Capital Management’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Bridgeway Capital Management’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,110
Closed -$326K – 1412
2018
Q4 		$326K Buy
+1,110
New +$265K ﹤0.01% 1111

Other funds holding CSCI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return

Bridgeway Capital Management's CSCI Position: Q1 2019 in Review

Bridgeway Capital Management sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q1 2019, closing a stake of 1,110 shares — an estimated $326K sold.

Bridgeway Capital Management first reported a position in CSCI in Q4 2018 and held it in 1 quarter. The position peaked at $326K in Q4 2018. 26 funds tracked by Wall St. Rank hold CSCI as of Q1 2019.

  • Bridgeway Capital Management reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Bridgeway Capital Management sold 1,110 COSCIENS Biopharma Inc. Common Stock shares in Q1 2019, an estimated $326K.
  • Bridgeway Capital Management first reported a position in COSCIENS Biopharma Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Bridgeway Capital Management's COSCIENS Biopharma Inc. Common Stock position peaked at $326K in Q4 2018.
  • 26 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q1 2019.

Based on Bridgeway Capital Management's 13F filing for Q1 2019, filed 15 May 2019.